


# INVION

LEADING THE GLOBAL  
CLINICAL DEVELOPMENT  
OF THE PHOTOSOFT™  
TECHNOLOGY FOR THE  
TREATMENT OF CANCERS





Skin cancers

Lung cancer

Prostate cancer  
Ovarian cancer


INVION IS DEVELOPING A NEW  
PHOTODYNAMIC THERAPY  
WITH A NOVEL  
PHOTOSENSITISER  
(PHOTOSOFT™ TECHNOLOGY)  
TO IMPROVE THE TREATMENT  
OF VARIOUS CANCERS

# PHOTOSOFT™ TECHNOLOGY ADVANTAGES

- Activation at multiple wavelengths allows for both diagnostic and therapeutic use
- Water soluble
- Can be administered via various routes – sublingual, topical and intravenous
- Positive immune response demonstrated in Phase I clinical trials


CURRENTLY AVAILABLE  
THERAPIES

1



PHOTOSOFT™

2



NEW  
GENERATION  
PDTs:  
**PHOTOSOFT™  
& IVX-P02**


## **Photosoft™**

- Chlorin-e4 based photosensitiser, multiple excitation peaks
- Blue light – strong red fluorescence for lesion visualization
- Red light – generation of ROS for directed tissue ablation
- Non-toxic and tolerated at high doses

## **IVX-P02**

- Next iteration of Photosoft™
- Topical and IV delivery and enhanced cytotoxicity

# 2018 A YEAR OF RAPID PROGRESS



# HIGHLY EXPERIENCED TEAM



**CRAIG NEWTON**  
Chief Operating  
Officer




**LOUISE WHITE**  
Manufacturing  
and Quality  
Advisor



**XENIA SANGO**  
Regulatory  
and Clinical  
Development



**ALEXANDER  
BENNETT**  
Technical  
Advisor




**DR SEBASTIAN  
MARCuccio**  
Chemistry  
Advisor



**DR ANDREW  
STEPHENS**  
Advisory  
Board  
member

# HUDSON INSTITUTE COLLABORATION PROMISING OVARIAN CANCER RESULTS



# INVION IN THE NEWS 2018

**STOCKHEAD** JUST IN RESOURCES TECH HEALTH EXPERTS



## Invion goes flying after Photosoft treatment shown to zap ovarian cancer cells

Health 7/5/2018 | Emma Koehn

Biotech Invion was flying this morning after telling investors the first tests of its Photosoft cancer fighting technology reveal the technique has the power to wipe out ovarian cancer cells.

The stock jumped 48 per cent from 3.3c to an intraday high of 4.9c in early trade before settling back to 3.8c at the close.

Invion (ASX:IVX) is a stand-out performer in the biotech space. Its share price is up 560 per cent compared with this time last year, while its market cap has risen from \$1.5 million to \$10.5 million.

**BUSINESS INSIDER AUSTRALIA**

TECH INSIDER

## Invion shares are flying after its tech shows potential to wipe out ovarian cancer cells

EMMA KOEHN, STOCKHEAD  
JUL 5, 2018, 11:29 AM

FACEBOOK TWITTER REDDIT LINKEDIN



**STOCKHEAD** JUST IN RESOURCES TECH HEALTH EXPERTS

SPINE IN DARKNESS WITH KALKINE TOP 25 DIVIDEND STOCKS REPORT CLICK HERE TO KNOW MORE



## Invion says its ovarian cancer cell killer is now 15x more deadly

Health September 25, 2018 | Daniel Parrish

HEAR IT FIRST WITH OUR DAILY NEWSLETTER

First Name:

Last Name:

Enter your email address:

SUBSCRIBE

**SMALL CAPS**

HOT TOPICS LATEST TOP STOCKS SECTORS IPOs TOOLS MEDIA

## Invion improves upon Photosoft non-immunosuppressive cancer therapy

By George Tchertvakov - September 25, 2018



**proactiveinvestors AUSTRALIA**




proactiveinvestors

**Herald Sun**

Search

HEALTH BODY+SOUL DAILY



Breakthrough Ovarian Cancer treatment

**ILLNESS**

## Breakthrough new treatment uses light to kill ovarian and skin cancer

**Sharecafe**

## Invion Tripping The Light To Fantastic Results

By James Dunn | More Articles by James Dunn



**INVION**

Dr Greg Collier  
CEO, Invion Limited

effective than Photosoft Oral cells.

Print Email

ted that it has managed to essive cancer therapy mulation of its proprietary

ment that can affect cancer ent chemotherapies.



# SKIN CANCER PROGRAM

## A POWERFUL NEW TREATMENT OPTION

Invion will be pursuing superficial BCC (sBCC) and Actinic Keratosis (AK)

### Product Characteristics

- Diagnostic and Therapeutic
- Topical Application
- Gel formulation
- Fast drying
- Incubation Time (up to 24 hours)
- Illumination with LED light source at 652 nm

Collaborations established:


### Formulytica

- Engaged to develop topical formulation of IVX-P02
- Ready for human clinical trials in 2019

### vivoPharm

- Engaged to undertake pre-clinical studies
- First data expected early 2019

# KEY MILESTONES AHEAD



## Multiple programs due to enter trials in 2019

- **Topical Indications:**
  - Skin cancer BCC
  - Actinic Keratosis
- **Intravenous Indications:**
  - Ovarian
  - Lung
  - Prostrate

# MARKET OVERVIEW

**\$0.024**


(At 9 November 2018)

**Mkt. Cap. A\$131m**

(At 9 November 2018)

<b>Focus</b>	Clinical-stage life sciences company
<b>Issued Shares</b>	5,492,272,967
<b>Cash (At 30 Sep 2018)</b>	AUD \$1.647M
<b>Funding</b>	Invion has an R&D services agreement with The Cho Group who provide non-dilutive funding for the clinical development of Photosoft™ technology.
<b>Symbol</b>	IVX
<b>Exchange</b>	ASX

## PRICE AND VOLUME



## Substantial shareholders

	%IC
UNLIMITED INNOVATION GROUP LIMITED	51.24
POLAR VENTURES LIMITED	9.93
MR HONSUE CHO	5.17

**INVION**<sup>™</sup>